Pfizer and BioNTech initiated rolling submission of Biologics License Application for FDA approval of COVID-19 vaccine
On May 7, 2021, Pfizer and BioNTech announced the initiation of a Biologics License Application (BLA) with the FDA for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. Data to support the BLA was submitted by the Companies to the FDA on a rolling basis over the coming weeks, with a request for Priority Review.
Tags:
Source: Pfizer
Credit: